8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Apr 3, 2026·SEC
Material company update
Mar 30, 2026·SEC
Kezar Life Sciences, Inc.(KZR)Earnings, Financials & Key Ratios
KZR•NASDAQ
$7.29
Price updated Jun 20, 2026
AboutKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$51M+42.6%
- Net Income-$56M+33.1%
- EPS (Diluted)-7.66-566.1%
- ROE-59.93%-9.0%
KZR Price & Volume
Kezar Life Sciences, Inc. (KZR) stock price & volume — 10-year historical chart
Loading chart...
Clinical Attrition Drives Severe Operational Contraction
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial failure risk
Key Thesis Takeaways
- Kezar Life Sciences faces a precarious outlook as the company has effectively pivoted away from its primary clinical programs following significant safety setbacks.
- The drastic reduction in R&D spending from $22.6M in 2023Q4 to $1.5M in 2026Q1 suggests a lack of viable near-term growth drivers.
- Investors should monitor the company's ability to preserve its remaining $66.2M cash balance while navigating the absence of any revenue-generating commercial pipeline.
Verdict Logic
the company's lack of revenue and the rapid depletion of total assets from $221.2M in 2023Q4 to $68.0M in 2026Q1 suggest a distressed asset profile with limited upside.
KZR Growth Metrics
Kezar Life Sciences, Inc. (KZR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM42.48%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-9.79%
Return on Capital
10 Years-43.14%
5 Years-42.74%
3 Years-51.44%
Last Year-53.77%
KZR Recent Earnings
Kezar Life Sciences, Inc. (KZR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.78+20.4%
$0.98
Rev
—
$1M
Q2 2026
Mar 27, 2026Metric
Actual
Est
EPS
$1.99-52.0%
$1.31
Rev
—
$333,330
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$1.53+15.5%
$1.81
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$1.87+13.0%
$2.15
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.78vs $0.98+20.4% | —vs $1M |
| Q2 2026 | Mar 27, 2026 | $1.99vs $1.31-52.0% | —vs $333,330 |
| Q4 2025 | Nov 12, 2025 | $1.53vs $1.81+15.5% | — |
| Q3 2025 | Aug 13, 2025 | $1.87vs $2.15+13.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Kezar Life Sciences, Inc. (KZR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.29 | $53.86M | -0.95 | — | — | -59.93% | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $26.07 | $3.26B | -200.54 | 91.34% | -0.57% | -1.41% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — | |
| $3.01 | $490.79M | -1.84 | — | — | -131.58% | — |
Compare KZR vs Peers
Kezar Life Sciences, Inc. (KZR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KZR SEC Filings & Documents
Kezar Life Sciences, Inc. (KZR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when KZR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KZR Frequently Asked Questions
Kezar Life Sciences, Inc. (KZR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is KZR profitable?
Kezar Life Sciences, Inc. (KZR) reported a net loss of $45.2M for fiscal year 2025.
Dividend & Returns
What is KZR's return on equity?
Kezar Life Sciences, Inc. (KZR) has a return on equity (ROE) of -59.9%. Negative ROE indicates the company is unprofitable.
What is Kezar Life Sciences, Inc.'s free cash flow?
Kezar Life Sciences, Inc. (KZR) had negative free cash flow of $42.0M in fiscal year 2025, likely due to heavy capital investments.